The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

Jefferies sees Arbutus (NASDAQ:ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE) ...

Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 4,599 call options on the company. This represents an increase of ...

The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...

Novavax (NASDAQ:NVAX), and other vaccine developers extended recent gains on Tuesday as investors reacted to rising flu and ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

Investors speculated on Covid vaccine firms. Despite the seasonal strength for flu-related vaccines ending, Moderna (MRNA) ...

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...